Guggenheim Raises Price Target Following Meetings with Jazz Pharmaceuticals (JAZZ)
Tweet Send to a Friend
Guggenheim maintains a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and raised the price target to $220.00 (from $210.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
